首页 > 最新文献

World Psychiatry最新文献

英文 中文
Management of generalized anxiety disorder and panic disorder in general health care settings: new WHO recommendations. 普通医疗机构对广泛性焦虑症和惊恐障碍的管理:世界卫生组织的新建议。
IF 73.3 1区 医学 Q1 PSYCHIATRY Pub Date : 2024-02-01 DOI: 10.1002/wps.21172
Brandon Gray, Biksegn Asrat, Elaine Brohan, Neerja Chowdhury, Tarun Dua, Mark van Ommeren
{"title":"Management of generalized anxiety disorder and panic disorder in general health care settings: new WHO recommendations.","authors":"Brandon Gray, Biksegn Asrat, Elaine Brohan, Neerja Chowdhury, Tarun Dua, Mark van Ommeren","doi":"10.1002/wps.21172","DOIUrl":"10.1002/wps.21172","url":null,"abstract":"","PeriodicalId":49357,"journal":{"name":"World Psychiatry","volume":"23 1","pages":"160-161"},"PeriodicalIF":73.3,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10785994/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139425856","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cumulative remission rate after sequential treatments in depression: reappraisal of the STAR*D trial data. 抑郁症连续治疗后的累积缓解率:对 STAR*D 试验数据的重新评估。
IF 60.5 1区 医学 Q1 PSYCHIATRY Pub Date : 2024-02-01 DOI: 10.1002/wps.21169
Hitoshi Sakurai, Hisashi Noma, Koichiro Watanabe, Hiroyuki Uchida, Toshi A Furukawa
{"title":"Cumulative remission rate after sequential treatments in depression: reappraisal of the STAR*D trial data.","authors":"Hitoshi Sakurai, Hisashi Noma, Koichiro Watanabe, Hiroyuki Uchida, Toshi A Furukawa","doi":"10.1002/wps.21169","DOIUrl":"10.1002/wps.21169","url":null,"abstract":"","PeriodicalId":49357,"journal":{"name":"World Psychiatry","volume":"23 1","pages":"156-157"},"PeriodicalIF":60.5,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10785965/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139425845","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Functional magnetic resonance imaging in schizophrenia: current evidence, methodological advances, limitations and future directions. 精神分裂症的功能磁共振成像:当前证据、方法学进展、局限性和未来方向。
IF 60.5 1区 医学 Q1 PSYCHIATRY Pub Date : 2024-02-01 DOI: 10.1002/wps.21159
Aristotle N Voineskos, Colin Hawco, Nicholas H Neufeld, Jessica A Turner, Stephanie H Ameis, Alan Anticevic, Robert W Buchanan, Kristin Cadenhead, Paola Dazzan, Erin W Dickie, Julia Gallucci, Adrienne C Lahti, Anil K Malhotra, Dost Öngür, Todd Lencz, Deepak K Sarpal, Lindsay D Oliver

Functional neuroimaging emerged with great promise and has provided fundamental insights into the neurobiology of schizophrenia. However, it has faced challenges and criticisms, most notably a lack of clinical translation. This paper provides a comprehensive review and critical summary of the literature on functional neuroimaging, in particular functional magnetic resonance imaging (fMRI), in schizophrenia. We begin by reviewing research on fMRI biomarkers in schizophrenia and the clinical high risk phase through a historical lens, moving from case-control regional brain activation to global connectivity and advanced analytical approaches, and more recent machine learning algorithms to identify predictive neuroimaging features. Findings from fMRI studies of negative symptoms as well as of neurocognitive and social cognitive deficits are then reviewed. Functional neural markers of these symptoms and deficits may represent promising treatment targets in schizophrenia. Next, we summarize fMRI research related to antipsychotic medication, psychotherapy and psychosocial interventions, and neurostimulation, including treatment response and resistance, therapeutic mechanisms, and treatment targeting. We also review the utility of fMRI and data-driven approaches to dissect the heterogeneity of schizophrenia, moving beyond case-control comparisons, as well as methodological considerations and advances, including consortia and precision fMRI. Lastly, limitations and future directions of research in the field are discussed. Our comprehensive review suggests that, in order for fMRI to be clinically useful in the care of patients with schizophrenia, research should address potentially actionable clinical decisions that are routine in schizophrenia treatment, such as which antipsychotic should be prescribed or whether a given patient is likely to have persistent functional impairment. The potential clinical utility of fMRI is influenced by and must be weighed against cost and accessibility factors. Future evaluations of the utility of fMRI in prognostic and treatment response studies may consider including a health economics analysis.

功能神经成像技术的出现带来了巨大的希望,并为精神分裂症的神经生物学提供了基本的见解。然而,它也面临着挑战和批评,其中最突出的是缺乏临床转化。本文对有关精神分裂症的功能神经成像,尤其是功能磁共振成像(fMRI)的文献进行了全面回顾和批判性总结。我们首先从历史的角度回顾了精神分裂症和临床高危阶段的 fMRI 生物标志物研究,从病例对照区域脑激活到全局连接和高级分析方法,以及最近的机器学习算法,以确定预测性神经影像特征。随后,我们将回顾有关消极症状以及神经认知和社会认知缺陷的 fMRI 研究结果。这些症状和缺陷的功能性神经标记可能是精神分裂症有希望的治疗目标。接下来,我们总结了与抗精神病药物治疗、心理治疗和社会心理干预以及神经刺激相关的 fMRI 研究,包括治疗反应和抗药性、治疗机制和治疗靶点。我们还回顾了 fMRI 和数据驱动方法在剖析精神分裂症异质性方面的效用(超越病例对照比较),以及方法学方面的考虑因素和进展,包括联合体和精准 fMRI。最后,还讨论了该领域研究的局限性和未来方向。我们的综合综述表明,为了使 fMRI 在精神分裂症患者的治疗中发挥临床作用,研究应针对精神分裂症治疗中常规的潜在可操作临床决策,如应处方哪种抗精神病药物或特定患者是否可能出现持续的功能障碍。fMRI 的潜在临床实用性受到成本和可及性因素的影响,必须对这些因素进行权衡。未来对 fMRI 在预后和治疗反应研究中的效用进行评估时,可考虑纳入卫生经济学分析。
{"title":"Functional magnetic resonance imaging in schizophrenia: current evidence, methodological advances, limitations and future directions.","authors":"Aristotle N Voineskos, Colin Hawco, Nicholas H Neufeld, Jessica A Turner, Stephanie H Ameis, Alan Anticevic, Robert W Buchanan, Kristin Cadenhead, Paola Dazzan, Erin W Dickie, Julia Gallucci, Adrienne C Lahti, Anil K Malhotra, Dost Öngür, Todd Lencz, Deepak K Sarpal, Lindsay D Oliver","doi":"10.1002/wps.21159","DOIUrl":"10.1002/wps.21159","url":null,"abstract":"<p><p>Functional neuroimaging emerged with great promise and has provided fundamental insights into the neurobiology of schizophrenia. However, it has faced challenges and criticisms, most notably a lack of clinical translation. This paper provides a comprehensive review and critical summary of the literature on functional neuroimaging, in particular functional magnetic resonance imaging (fMRI), in schizophrenia. We begin by reviewing research on fMRI biomarkers in schizophrenia and the clinical high risk phase through a historical lens, moving from case-control regional brain activation to global connectivity and advanced analytical approaches, and more recent machine learning algorithms to identify predictive neuroimaging features. Findings from fMRI studies of negative symptoms as well as of neurocognitive and social cognitive deficits are then reviewed. Functional neural markers of these symptoms and deficits may represent promising treatment targets in schizophrenia. Next, we summarize fMRI research related to antipsychotic medication, psychotherapy and psychosocial interventions, and neurostimulation, including treatment response and resistance, therapeutic mechanisms, and treatment targeting. We also review the utility of fMRI and data-driven approaches to dissect the heterogeneity of schizophrenia, moving beyond case-control comparisons, as well as methodological considerations and advances, including consortia and precision fMRI. Lastly, limitations and future directions of research in the field are discussed. Our comprehensive review suggests that, in order for fMRI to be clinically useful in the care of patients with schizophrenia, research should address potentially actionable clinical decisions that are routine in schizophrenia treatment, such as which antipsychotic should be prescribed or whether a given patient is likely to have persistent functional impairment. The potential clinical utility of fMRI is influenced by and must be weighed against cost and accessibility factors. Future evaluations of the utility of fMRI in prognostic and treatment response studies may consider including a health economics analysis.</p>","PeriodicalId":49357,"journal":{"name":"World Psychiatry","volume":"23 1","pages":"26-51"},"PeriodicalIF":60.5,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10786022/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139425851","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Genetics for mental health clinicians: a call for a globally accessible and equitable psychiatric genetics education. 精神卫生临床医生的遗传学:呼吁在全球范围内开展公平的精神遗传学教育。
IF 60.5 1区 医学 Q1 PSYCHIATRY Pub Date : 2024-02-01 DOI: 10.1002/wps.21173
{"title":"Genetics for mental health clinicians: a call for a globally accessible and equitable psychiatric genetics education.","authors":"","doi":"10.1002/wps.21173","DOIUrl":"10.1002/wps.21173","url":null,"abstract":"","PeriodicalId":49357,"journal":{"name":"World Psychiatry","volume":"23 1","pages":"161-163"},"PeriodicalIF":60.5,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10785985/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139425854","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Risk of new-onset psychiatric sequelae of COVID-19 in the early and late post-acute phase. COVID - 19急性期早期和晚期新发精神后遗症的风险
IF 73.3 1区 医学 Q1 PSYCHIATRY Pub Date : 2022-06-01 DOI: 10.1002/wps.20992
Ben Coleman, Elena Casiraghi, Hannah Blau, Lauren Chan, Melissa A Haendel, Bryan Laraway, Tiffany J Callahan, Rachel R Deer, Kenneth J Wilkins, Justin Reese, Peter N Robinson
319 half of the originally randomized sample. However, almost half (43.8%) of the omitted participants simply did not receive the assessment needed to diagnose PGD, and another 38% were excluded because it was too soon (six months to one year since the loss) to receive a PGD diagnosis. Further, those assessed showed no differences in demographic or clinical characteristics from participants in the parent study. We endorse continued study of effective treatments for PGD. In the meantime, we believe that clinicians will benefit from knowing that CGT, a strongly validated intervention, can be appropriately re-labeled as prolonged grief disorder therapy (PGDT).
319是最初随机抽样的一半。然而,几乎一半(43.8%)被忽略的参与者根本没有接受诊断PGD所需的评估,另外38%被排除是因为太早(自失去后6个月到1年)接受PGD诊断。此外,这些评估显示,在人口统计学或临床特征与父母研究的参与者没有差异。我们支持继续研究PGD的有效治疗方法。同时,我们相信临床医生将受益于知道CGT,一个强有力的验证干预,可以适当地重新标记为延长悲伤障碍治疗(PGDT)。
{"title":"Risk of new-onset psychiatric sequelae of COVID-19 in the early and late post-acute phase.","authors":"Ben Coleman,&nbsp;Elena Casiraghi,&nbsp;Hannah Blau,&nbsp;Lauren Chan,&nbsp;Melissa A Haendel,&nbsp;Bryan Laraway,&nbsp;Tiffany J Callahan,&nbsp;Rachel R Deer,&nbsp;Kenneth J Wilkins,&nbsp;Justin Reese,&nbsp;Peter N Robinson","doi":"10.1002/wps.20992","DOIUrl":"10.1002/wps.20992","url":null,"abstract":"319 half of the originally randomized sample. However, almost half (43.8%) of the omitted participants simply did not receive the assessment needed to diagnose PGD, and another 38% were excluded because it was too soon (six months to one year since the loss) to receive a PGD diagnosis. Further, those assessed showed no differences in demographic or clinical characteristics from participants in the parent study. We endorse continued study of effective treatments for PGD. In the meantime, we believe that clinicians will benefit from knowing that CGT, a strongly validated intervention, can be appropriately re-labeled as prolonged grief disorder therapy (PGDT).","PeriodicalId":49357,"journal":{"name":"World Psychiatry","volume":"21 1","pages":"319-320"},"PeriodicalIF":73.3,"publicationDate":"2022-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9077621/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46561566","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 13
Prevention, treatment and care of substance use disorders in times of COVID-19. COVID - 19期间物质使用障碍的预防、治疗和护理
IF 60.5 1区 医学 Q1 PSYCHIATRY Pub Date : 2022-06-01 DOI: 10.1002/wps.20995
Nora D Volkow, Susan Maua, Giovanna Campello, Vladimir Poznyak, Dzmitry Krupchanka, Wataru Kashino, Anja Busse
{"title":"Prevention, treatment and care of substance use disorders in times of COVID-19.","authors":"Nora D Volkow, Susan Maua, Giovanna Campello, Vladimir Poznyak, Dzmitry Krupchanka, Wataru Kashino, Anja Busse","doi":"10.1002/wps.20995","DOIUrl":"10.1002/wps.20995","url":null,"abstract":"","PeriodicalId":49357,"journal":{"name":"World Psychiatry","volume":"21 1","pages":"323-324"},"PeriodicalIF":60.5,"publicationDate":"2022-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9077610/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45037505","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Patterns and correlates of patient-reported helpfulness of treatment for common mental and substance use disorders in the WHO World Mental Health Surveys. 世卫组织世界精神卫生调查中患者报告的对治疗常见精神和物质使用障碍的帮助程度的模式和相关因素
IF 60.5 1区 医学 Q1 PSYCHIATRY Pub Date : 2022-06-01 DOI: 10.1002/wps.20971
Ronald C Kessler, Alan E Kazdin, Sergio Aguilar-Gaxiola, Ali Al-Hamzawi, Jordi Alonso, Yasmin A Altwaijri, Laura H Andrade, Corina Benjet, Chrianna Bharat, Guilherme Borges, Ronny Bruffaerts, Brendan Bunting, José Miguel Caldas de Almeida, Graça Cardoso, Wai Tat Chiu, Alfredo Cía, Marius Ciutan, Louisa Degenhardt, Giovanni de Girolamo, Peter de Jonge, Ymkje Anna de Vries, Silvia Florescu, Oye Gureje, Josep Maria Haro, Meredith G Harris, Chiyi Hu, Aimee N Karam, Elie G Karam, Georges Karam, Norito Kawakami, Andrzej Kiejna, Viviane Kovess-Masfety, Sing Lee, Victor Makanjuola, John J McGrath, Maria Elena Medina-Mora, Jacek Moskalewicz, Fernando Navarro-Mateu, Andrew A Nierenberg, Daisuke Nishi, Akin Ojagbemi, Bibilola D Oladeji, Siobhan O'Neill, José Posada-Villa, Victor Puac-Polanco, Charlene Rapsey, Ayelet Meron Ruscio, Nancy A Sampson, Kate M Scott, Tim Slade, Juan Carlos Stagnaro, Dan J Stein, Hisateru Tachimori, Margreet Ten Have, Yolanda Torres, Maria Carmen Viana, Daniel V Vigo, David R Williams, Bogdan Wojtyniak, Miguel Xavier, Zahari Zarkov, Hannah N Ziobrowski

Patient-reported helpfulness of treatment is an important indicator of quality in patient-centered care. We examined its pathways and predictors among respondents to household surveys who reported ever receiving treatment for major depression, generalized anxiety disorder, social phobia, specific phobia, post-traumatic stress disorder, bipolar disorder, or alcohol use disorder. Data came from 30 community epidemiological surveys - 17 in high-income countries (HICs) and 13 in low- and middle-income countries (LMICs) - carried out as part of the World Health Organization (WHO)'s World Mental Health (WMH) Surveys. Respondents were asked whether treatment of each disorder was ever helpful and, if so, the number of professionals seen before receiving helpful treatment. Across all surveys and diagnostic categories, 26.1% of patients (N=10,035) reported being helped by the very first professional they saw. Persisting to a second professional after a first unhelpful treatment brought the cumulative probability of receiving helpful treatment to 51.2%. If patients persisted with up through eight professionals, the cumulative probability rose to 90.6%. However, only an estimated 22.8% of patients would have persisted in seeing these many professionals after repeatedly receiving treatments they considered not helpful. Although the proportion of individuals with disorders who sought treatment was higher and they were more persistent in HICs than LMICs, proportional helpfulness among treated cases was no different between HICs and LMICs. A wide range of predictors of perceived treatment helpfulness were found, some of them consistent across diagnostic categories and others unique to specific disorders. These results provide novel information about patient evaluations of treatment across diagnoses and countries varying in income level, and suggest that a critical issue in improving the quality of care for mental disorders should be fostering persistence in professional help-seeking if earlier treatments are not helpful.

患者报告的治疗有用性是以患者为中心的护理质量的重要指标。我们在家庭调查的受访者中研究了其途径和预测因素,这些受访者报告曾接受过严重抑郁症、广泛性焦虑症、社交恐惧症、特定恐惧症、创伤后应激障碍、双相情感障碍或酒精使用障碍的治疗。数据来自30项社区流行病学调查——17项在高收入国家(HIC),13项在低收入和中等收入国家(LMIC)——作为世界卫生组织(世界卫生组织)世界心理健康(WMH)调查的一部分。受访者被问及每种疾病的治疗是否有帮助,如果有,在接受有益治疗之前,有多少专业人员就诊。在所有调查和诊断类别中,26.1%的患者(N=10035)报告说,他们看到的第一位专业人士就帮助了他们。在第一次无效治疗后,坚持第二位专业人员治疗,使患者获得有效治疗的累计概率达到51.2%。如果患者坚持使用八位专业人员,累计概率上升至90.6%。然而,据估计,只有22.8%的患者在反复接受他们认为没有帮助的治疗后,会坚持去看这么多专业人士。尽管与LMIC相比,患有疾病的患者寻求治疗的比例更高,并且他们在HIC中更持久,但HIC和LMIC之间治疗病例的帮助比例没有什么不同。发现了一系列感知治疗有用性的预测因素,其中一些在诊断类别中是一致的,另一些则是特定疾病特有的。这些结果提供了关于不同诊断和收入水平国家的患者治疗评估的新信息,并表明,如果早期治疗没有帮助,提高精神障碍护理质量的一个关键问题应该是培养持续寻求专业帮助的能力。
{"title":"Patterns and correlates of patient-reported helpfulness of treatment for common mental and substance use disorders in the WHO World Mental Health Surveys.","authors":"Ronald C Kessler, Alan E Kazdin, Sergio Aguilar-Gaxiola, Ali Al-Hamzawi, Jordi Alonso, Yasmin A Altwaijri, Laura H Andrade, Corina Benjet, Chrianna Bharat, Guilherme Borges, Ronny Bruffaerts, Brendan Bunting, José Miguel Caldas de Almeida, Graça Cardoso, Wai Tat Chiu, Alfredo Cía, Marius Ciutan, Louisa Degenhardt, Giovanni de Girolamo, Peter de Jonge, Ymkje Anna de Vries, Silvia Florescu, Oye Gureje, Josep Maria Haro, Meredith G Harris, Chiyi Hu, Aimee N Karam, Elie G Karam, Georges Karam, Norito Kawakami, Andrzej Kiejna, Viviane Kovess-Masfety, Sing Lee, Victor Makanjuola, John J McGrath, Maria Elena Medina-Mora, Jacek Moskalewicz, Fernando Navarro-Mateu, Andrew A Nierenberg, Daisuke Nishi, Akin Ojagbemi, Bibilola D Oladeji, Siobhan O'Neill, José Posada-Villa, Victor Puac-Polanco, Charlene Rapsey, Ayelet Meron Ruscio, Nancy A Sampson, Kate M Scott, Tim Slade, Juan Carlos Stagnaro, Dan J Stein, Hisateru Tachimori, Margreet Ten Have, Yolanda Torres, Maria Carmen Viana, Daniel V Vigo, David R Williams, Bogdan Wojtyniak, Miguel Xavier, Zahari Zarkov, Hannah N Ziobrowski","doi":"10.1002/wps.20971","DOIUrl":"10.1002/wps.20971","url":null,"abstract":"<p><p>Patient-reported helpfulness of treatment is an important indicator of quality in patient-centered care. We examined its pathways and predictors among respondents to household surveys who reported ever receiving treatment for major depression, generalized anxiety disorder, social phobia, specific phobia, post-traumatic stress disorder, bipolar disorder, or alcohol use disorder. Data came from 30 community epidemiological surveys - 17 in high-income countries (HICs) and 13 in low- and middle-income countries (LMICs) - carried out as part of the World Health Organization (WHO)'s World Mental Health (WMH) Surveys. Respondents were asked whether treatment of each disorder was ever helpful and, if so, the number of professionals seen before receiving helpful treatment. Across all surveys and diagnostic categories, 26.1% of patients (N=10,035) reported being helped by the very first professional they saw. Persisting to a second professional after a first unhelpful treatment brought the cumulative probability of receiving helpful treatment to 51.2%. If patients persisted with up through eight professionals, the cumulative probability rose to 90.6%. However, only an estimated 22.8% of patients would have persisted in seeing these many professionals after repeatedly receiving treatments they considered not helpful. Although the proportion of individuals with disorders who sought treatment was higher and they were more persistent in HICs than LMICs, proportional helpfulness among treated cases was no different between HICs and LMICs. A wide range of predictors of perceived treatment helpfulness were found, some of them consistent across diagnostic categories and others unique to specific disorders. These results provide novel information about patient evaluations of treatment across diagnoses and countries varying in income level, and suggest that a critical issue in improving the quality of care for mental disorders should be fostering persistence in professional help-seeking if earlier treatments are not helpful.</p>","PeriodicalId":49357,"journal":{"name":"World Psychiatry","volume":" ","pages":"272-286"},"PeriodicalIF":60.5,"publicationDate":"2022-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9077614/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45958830","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Reasons why people may refuse COVID‐19 vaccination (and what can be done about it) 人们可能拒绝接种新冠疫苗的原因(以及可以采取的措施)
IF 73.3 1区 医学 Q1 PSYCHIATRY Pub Date : 2022-05-07 DOI: 10.1002/wps.20990
M. Hornsey
{"title":"Reasons why people may refuse COVID‐19 vaccination (and what can be done about it)","authors":"M. Hornsey","doi":"10.1002/wps.20990","DOIUrl":"https://doi.org/10.1002/wps.20990","url":null,"abstract":"","PeriodicalId":49357,"journal":{"name":"World Psychiatry","volume":"21 1","pages":"217 - 218"},"PeriodicalIF":73.3,"publicationDate":"2022-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44037982","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Oral and long‐acting antipsychotics for relapse prevention in schizophrenia‐spectrum disorders: a network meta‐analysis of 92 randomized trials including 22,645 participants 口服和长效抗精神病药物预防精神分裂症谱系障碍复发:92项随机试验的网络荟萃分析,包括22645名参与者
IF 73.3 1区 医学 Q1 PSYCHIATRY Pub Date : 2022-05-07 DOI: 10.1002/wps.20972
G. Ostuzzi, F. Bertolini, F. Tedeschi, Giovanni Vita, P. Brambilla, L. Fabro, C. Gastaldon, D. Papola, M. Purgato, Guido Nosari, C. Del Giovane, C. Correll, C. Barbui
According to current evidence and guidelines, continued antipsychotic treatment is key for preventing relapse in people with schizophrenia‐spectrum disorders, but evidence‐based recommendations for the choice of the individual antipsychotic for maintenance treatment are lacking. Although oral antipsychotics are often prescribed first line for practical reasons, long‐acting injectable antipsychotics (LAIs) are a valuable resource to tackle adherence issues since the earliest phase of disease. Medline, EMBASE, PsycINFO, CENTRAL and CINAHL databases and online registers were searched to identify randomized controlled trials comparing LAIs or oral antipsychotics head‐to‐head or against placebo, published until June 2021. Relative risks and standardized mean differences were pooled using random‐effects pairwise and network meta‐analysis. The primary outcomes were relapse and dropout due to adverse events. We used the Cochrane Risk of Bias tool to assess study quality, and the CINeMA approach to assess the confidence of pooled estimates. Of 100 eligible trials, 92 (N=22,645) provided usable data for meta‐analyses. Regarding relapse prevention, the vast majority of the 31 included treatments outperformed placebo. Compared to placebo, “high” confidence in the results was found for (in descending order of effect magnitude) amisulpride‐oral (OS), olanzapine‐OS, aripiprazole‐LAI, olanzapine‐LAI, aripiprazole‐OS, paliperidone‐OS, and ziprasidone‐OS. “Moderate” confidence in the results was found for paliperidone‐LAI 1‐monthly, iloperidone‐OS, fluphenazine‐OS, brexpiprazole‐OS, paliperidone‐LAI 1‐monthly, asenapine‐OS, haloperidol‐OS, quetiapine‐OS, cariprazine‐OS, and lurasidone‐OS. Regarding tolerability, none of the antipsychotics was significantly worse than placebo, but confidence was poor, with only aripiprazole (both LAI and OS) showing “moderate” confidence levels. Based on these findings, olanzapine, aripiprazole and paliperidone are the best choices for the maintenance treatment of schizophrenia‐spectrum disorders, considering that both LAI and oral formulations of these antipsychotics are among the best‐performing treatments and have the highest confidence of evidence for relapse prevention. This finding is of particular relevance for low‐ and middle‐income countries and constrained‐resource settings, where few medications may be selected. Results from this network meta‐analysis can inform clinical guidelines and national and international drug regulation policies.
根据目前的证据和指南,持续的抗精神病药物治疗是预防精神分裂症谱系障碍患者复发的关键,但缺乏基于证据的关于选择个体抗精神病药进行维持治疗的建议。尽管出于实际原因,口服抗精神病药物通常是一线处方,但长效注射抗精神病药(LAI)是解决疾病早期依从性问题的宝贵资源。检索Medline、EMBASE、PsycINFO、CENTRAL和CINAHL数据库和在线注册,以确定将LAI或口服抗精神病药物与安慰剂进行正面或正面比较的随机对照试验,该试验于2021年6月发布。使用随机效应配对和网络荟萃分析将相对风险和标准化平均差异汇总。主要结果是复发和因不良事件而辍学。我们使用Cochrane偏倚风险工具来评估研究质量,并使用CINeMA方法来评估合并估计的置信度。在100项符合条件的试验中,92项(N=22645)为荟萃分析提供了可用数据。在预防复发方面,纳入的31种治疗中,绝大多数都优于安慰剂。与安慰剂相比,口服氨磺酰亚胺(OS)、奥氮平、阿立哌唑-LAI、奥氮平-LAI、阿立哌唑-OS、帕利培酮-OS和齐拉西酮-OS的结果置信度“较高”。帕利哌酮-LAI每月1次、伊洛哌酮-OS、氟奋乃嗪-OS、布瑞哌唑-OS、帕利哌醇-LAI每月一次、阿塞那平-OS、氟哌啶醇-OS、喹硫平-OS,卡哌嗪-OS和鲁拉西酮-OS对结果的置信度为“中等”。就耐受性而言,没有一种抗精神病药物比安慰剂明显差,但置信度较差,只有阿立哌唑(LAI和OS)显示出“中等”置信水平。基于这些发现,奥氮平、阿立哌唑和帕利培酮是维持治疗精神分裂症谱系障碍的最佳选择,因为这些抗精神病药物的LAI和口服制剂都是最好的治疗方法,并且对预防复发的证据有最高的信心。这一发现与低收入和中等收入国家以及资源有限的环境特别相关,因为这些国家可能很少选择药物。该网络荟萃分析的结果可以为临床指南以及国家和国际药品监管政策提供信息。
{"title":"Oral and long‐acting antipsychotics for relapse prevention in schizophrenia‐spectrum disorders: a network meta‐analysis of 92 randomized trials including 22,645 participants","authors":"G. Ostuzzi, F. Bertolini, F. Tedeschi, Giovanni Vita, P. Brambilla, L. Fabro, C. Gastaldon, D. Papola, M. Purgato, Guido Nosari, C. Del Giovane, C. Correll, C. Barbui","doi":"10.1002/wps.20972","DOIUrl":"https://doi.org/10.1002/wps.20972","url":null,"abstract":"According to current evidence and guidelines, continued antipsychotic treatment is key for preventing relapse in people with schizophrenia‐spectrum disorders, but evidence‐based recommendations for the choice of the individual antipsychotic for maintenance treatment are lacking. Although oral antipsychotics are often prescribed first line for practical reasons, long‐acting injectable antipsychotics (LAIs) are a valuable resource to tackle adherence issues since the earliest phase of disease. Medline, EMBASE, PsycINFO, CENTRAL and CINAHL databases and online registers were searched to identify randomized controlled trials comparing LAIs or oral antipsychotics head‐to‐head or against placebo, published until June 2021. Relative risks and standardized mean differences were pooled using random‐effects pairwise and network meta‐analysis. The primary outcomes were relapse and dropout due to adverse events. We used the Cochrane Risk of Bias tool to assess study quality, and the CINeMA approach to assess the confidence of pooled estimates. Of 100 eligible trials, 92 (N=22,645) provided usable data for meta‐analyses. Regarding relapse prevention, the vast majority of the 31 included treatments outperformed placebo. Compared to placebo, “high” confidence in the results was found for (in descending order of effect magnitude) amisulpride‐oral (OS), olanzapine‐OS, aripiprazole‐LAI, olanzapine‐LAI, aripiprazole‐OS, paliperidone‐OS, and ziprasidone‐OS. “Moderate” confidence in the results was found for paliperidone‐LAI 1‐monthly, iloperidone‐OS, fluphenazine‐OS, brexpiprazole‐OS, paliperidone‐LAI 1‐monthly, asenapine‐OS, haloperidol‐OS, quetiapine‐OS, cariprazine‐OS, and lurasidone‐OS. Regarding tolerability, none of the antipsychotics was significantly worse than placebo, but confidence was poor, with only aripiprazole (both LAI and OS) showing “moderate” confidence levels. Based on these findings, olanzapine, aripiprazole and paliperidone are the best choices for the maintenance treatment of schizophrenia‐spectrum disorders, considering that both LAI and oral formulations of these antipsychotics are among the best‐performing treatments and have the highest confidence of evidence for relapse prevention. This finding is of particular relevance for low‐ and middle‐income countries and constrained‐resource settings, where few medications may be selected. Results from this network meta‐analysis can inform clinical guidelines and national and international drug regulation policies.","PeriodicalId":49357,"journal":{"name":"World Psychiatry","volume":" ","pages":""},"PeriodicalIF":73.3,"publicationDate":"2022-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47199809","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 33
The “Meet the WPA Council” Panel at the 21st World Congress of Psychiatry 第21届世界精神病学大会“会见WPA理事会”小组
IF 73.3 1区 医学 Q1 PSYCHIATRY Pub Date : 2022-05-07 DOI: 10.1002/wps.20957
A. Okasha
{"title":"The “Meet the WPA Council” Panel at the 21st World Congress of Psychiatry","authors":"A. Okasha","doi":"10.1002/wps.20957","DOIUrl":"https://doi.org/10.1002/wps.20957","url":null,"abstract":"","PeriodicalId":49357,"journal":{"name":"World Psychiatry","volume":" ","pages":""},"PeriodicalIF":73.3,"publicationDate":"2022-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44067894","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
World Psychiatry
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1